Alkermes (ALKS) to Release Earnings on Wednesday

Alkermes (NASDAQ:ALKS) is expected to announce its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $380.4410 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 13, 2026 at 12:30 PM ET.

Alkermes Price Performance

Shares of NASDAQ:ALKS opened at $34.47 on Wednesday. Alkermes has a 1 year low of $25.17 and a 1 year high of $36.45. The business’s 50-day moving average is $30.06 and its 200-day moving average is $29.46. The company has a market capitalization of $5.69 billion, a price-to-earnings ratio of 17.06 and a beta of 0.49.

Wall Street Analysts Forecast Growth

ALKS has been the topic of several recent analyst reports. Zacks Research raised Alkermes from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 13th. Jefferies Financial Group set a $56.00 target price on shares of Alkermes and gave the company a “buy” rating in a research report on Tuesday, October 28th. Truist Financial lifted their price target on shares of Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reissued a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. Finally, Piper Sandler restated an “overweight” rating and issued a $45.00 target price (up from $38.00) on shares of Alkermes in a research note on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Alkermes currently has an average rating of “Moderate Buy” and a consensus price target of $44.69.

Insider Transactions at Alkermes

In related news, Director Shane Cooke sold 61,200 shares of Alkermes stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the transaction, the director owned 103,744 shares of the company’s stock, valued at $3,586,430.08. The trade was a 37.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Craig C. Hopkinson sold 9,000 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $33.93, for a total value of $305,370.00. Following the completion of the sale, the executive vice president directly owned 57,740 shares of the company’s stock, valued at $1,959,118.20. The trade was a 13.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 148,148 shares of company stock valued at $5,028,378 in the last quarter. Company insiders own 4.40% of the company’s stock.

Institutional Trading of Alkermes

Several institutional investors and hedge funds have recently made changes to their positions in ALKS. State Street Corp lifted its position in shares of Alkermes by 2.3% during the second quarter. State Street Corp now owns 8,208,256 shares of the company’s stock valued at $234,838,000 after purchasing an additional 185,586 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Alkermes by 19.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,697,996 shares of the company’s stock valued at $110,925,000 after buying an additional 601,359 shares during the last quarter. Holocene Advisors LP lifted its position in shares of Alkermes by 31.2% during the 2nd quarter. Holocene Advisors LP now owns 2,853,768 shares of the company’s stock worth $81,646,000 after buying an additional 679,166 shares in the last quarter. Commodore Capital LP boosted its stake in shares of Alkermes by 25.6% in the 2nd quarter. Commodore Capital LP now owns 2,450,000 shares of the company’s stock worth $70,094,000 after buying an additional 500,000 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Alkermes by 43.0% in the second quarter. Bank of America Corp DE now owns 2,155,087 shares of the company’s stock valued at $61,657,000 after acquiring an additional 647,905 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.